OPERA
Mark Identification

OPERA

Serial Number

90171690

Filing Date

Sep 10, 2020

Trademark by

KORRO BIO INC.

Classification Information

Oligonucleotide compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA compounds being a component in pharmaceutical preparations for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; RNA therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds being a component in pharmaceutical preparations for use in RNA editing; Oligonucleotide compounds being a component in pharmaceutical preparations for use in base editing; Oligonucleotide compounds being a component in pharmaceutical preparations for use as RNA therapeutic for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; Oligonucleotide compounds that facilitate the editing of RNA base; Pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars and therapeutics, namely, nucleic acid therapeutics for the treatment of genetic diseases and the repair and modulation of disease causing mutations and protein function; pharmaceuticals, namely, bio-pharmaceutical preparations for the treatment of rare diseases

Pharmaceuticals

Custom manufacture of oligonucleotides or RNAs for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders

Treatment of Materials

Research and development of pharmaceutical products; research and development in the field of bioscience; research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders; research and development of pharmaceutical preparations for the treatment of liver-based disorders, eye disorders and CNS disorders; research and development of oligonucleotide compounds for targeted RNA editing; research and development of oligonucleotide drug platforms for use in the treatment of various conditions, diseases and disorders, including rare diseases, genetic disorders, liver diseases, eye diseases, and CNS disorders

Computer and Scientific